Integration of viral DNA into the host genome is a central event in the replication cycle and
the pathogenesis of retroviruses, including HIV. Although most cells infected with HIV are …

A substantial research effort has been directed to identifying strategies to eradicate or
control HIV infection without a requirement for combination antiretroviral therapy (cART). A …

The latent HIV-1 reservoir in blood decays very slowly, even during prolonged suppression
of viral replication by antiretroviral therapy (ART). Mechanisms for reservoir persistence …

The barrier to curing HIV-1 is thought to reside primarily in CD4+ T cells containing silent
proviruses. To characterize these latently infected cells, we studied the integration profile of …

Advances in technology have made it possible to analyze integration sites in cells from HIV-
infected patients. A significant fraction of infected cells in patients on long-term therapy are …

Despite antiretroviral therapy (ART), HIV-1 persists as proviruses integrated into the
genomic DNA of CD4+ T cells. The mechanisms underlying the persistence and clonal …

Combination anti-retroviral therapy (cART) has drastically improved the clinical outcome of
HIV-1 infection. Nonetheless, despite effective cART, HIV-1 persists indefinitely in infected …

Despite antiretroviral therapy (ART) which halts HIV-1 replication and reduces plasma viral
load to clinically undetectable levels, viral rebound inevitably occurs once ART is …

HIV persists during antiretroviral therapy (ART) as integrated proviruses in cells descended
from a small fraction of the CD4+ T cells infected prior to the initiation of ART. To better …

Viral rebound upon stopping combined antiretroviral therapy poses a major barrier toward
an HIV cure. Cellular and anatomical sources responsible for reinitiating viral replication …